021-51111890
购物车（）
sales@molnova.cn
ACY-775
CAS No. 1375466-18-4
ACY-775 ( ACY 775;ACY775 )
产品货号. M11553 CAS No. 1375466-18-4
ACY-775 (ACY775) is a potent and specific HDAC6 inhibitor (IC50=7.5 nM) with improved brain bioavailability.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥348 | 有现货 |
|
| 5MG | ￥583 | 有现货 |
|
| 10MG | ￥988 | 有现货 |
|
| 25MG | ￥2066 | 有现货 |
|
| 50MG | ￥3345 | 有现货 |
|
| 100MG | ￥5006 | 有现货 |
|
| 500MG | ￥10773 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ACY-775
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ACY-775 (ACY775) is a potent and specific HDAC6 inhibitor (IC50=7.5 nM) with improved brain bioavailability.
-
产品描述ACY-775 (ACY775) is a potent and specific HDAC6 inhibitor (IC50=7.5 nM) with improved brain bioavailability; 60-1500 fold selectivity over class I HDACs; no activity against all other class II HDAC isoforms (IC50>1uM); induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model.
-
同义词ACY 775;ACY775
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC
-
研究领域——
-
适应症——
化学信息
-
CAS Number1375466-18-4
-
分子量330.36
-
分子式C17H19FN4O2
-
纯度>98% (HPLC)
-
溶解度DMSO : 100 mg/mL 302.70 mM
-
SMILESO=C(C1=CN=C(NC2(C3=CC=CC(F)=C3)CCCCC2)N=C1)NO
-
化学全称2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Jochems J, et al. Neuropsychopharmacology. 2014 Jan;39(2):389-400.
2. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
2. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
产品手册
关联产品
-
TMP-269
A potent and selective class IIa HDAC inhibitor.
-
Nexturastat A
A potent and selective HDAC6 inhibitor with IC50 of 5 nM.
-
Exifone
Exifone is a mixed, nonessential activator of HDAC1 that is capable of binding to both free and substrate-bound enzyme, resulting in an increased relative maximal rate of HDAC1-catalyzed deacetylation.
